Difficulty: Medium
Average Score: 79%
Practice
Which of the following findings would suggest that myelosuppression is occurring in a client who is taking zidovudine? (Retrovir)
Correct answer
C
Rationale
In the context of safety pharmacology, understanding the potential adverse effects of medications is crucial for healthcare professionals. Zidovudine (Retrovir) is an antiretroviral medication commonly used in the treatment of HIV/AIDS. Myelosuppression is a known side effect of zidovudine, which refers to a decrease in the production of blood cells in the bone marrow.
The correct answer is C) decrease in platelet count. Platelets are a type of blood cell that is essential for blood clotting. A decrease in platelet count indicates myelosuppression, as zidovudine can inhibit the production of platelets in the bone marrow, leading to an increased risk of bleeding and bruising.
Option A) increase in BUN levels is incorrect because it is a measure of kidney function, not directly related to myelosuppression caused by zidovudine. Option B) increase in WBC count is incorrect because zidovudine typically causes bone marrow suppression, leading to a decrease rather than an increase in white blood cell count. Option D) decrease in BP is unrelated to myelosuppression and is not a typical side effect of zidovudine.
Educationally, understanding the specific laboratory findings associated with myelosuppression caused by zidovudine is essential for healthcare providers to monitor and manage potential adverse effects in patients. Recognizing the significance of a decrease in platelet count can prompt timely intervention to prevent complications such as bleeding disorders in individuals taking zidovudine.
The correct answer is C) decrease in platelet count. Platelets are a type of blood cell that is essential for blood clotting. A decrease in platelet count indicates myelosuppression, as zidovudine can inhibit the production of platelets in the bone marrow, leading to an increased risk of bleeding and bruising.
Option A) increase in BUN levels is incorrect because it is a measure of kidney function, not directly related to myelosuppression caused by zidovudine. Option B) increase in WBC count is incorrect because zidovudine typically causes bone marrow suppression, leading to a decrease rather than an increase in white blood cell count. Option D) decrease in BP is unrelated to myelosuppression and is not a typical side effect of zidovudine.
Educationally, understanding the specific laboratory findings associated with myelosuppression caused by zidovudine is essential for healthcare providers to monitor and manage potential adverse effects in patients. Recognizing the significance of a decrease in platelet count can prompt timely intervention to prevent complications such as bleeding disorders in individuals taking zidovudine.